{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-24-003556","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.063216+00:00","generated_at":"2026-05-30T02:50:41.899942+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entera Bio Q3 net loss $3.0M ($0.08/shr); cash $6.9M; awaits FDA SABRE ruling Jan 2025","bullets":["Net loss of $3.0M ($0.08 basic/diluted EPS) for Q3 2024 vs $2.4M ($0.08) in Q3 2023; operating expenses $3.0M vs $2.4M.","Cash and equivalents $6.9M; expects runway into Q3 2025.","EB613 (oral PTH) phase 3 prep ongoing; FDA decision on SABRE regulatory endpoint expected January 2025.","Oral GLP-1/glucagon (with OPKO) showed favorable PK/PD; plans to present at clinical conference.","Oral GLP-2 tablet for short bowel syndrome; final PK/PD data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-24-003556","json":"https://secwatch.observer/filing/0001178913-24-003556.json","markdown":"https://secwatch.observer/filing/0001178913-24-003556.md","text":"https://secwatch.observer/filing/0001178913-24-003556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324003556/0001178913-24-003556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324003556/zk2432254.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:50:41.899942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}